Can’t Stop, Won’t Stop the Search for Relief: Scratching the Surface of Itch and Inflammation in Moderate-to-Severe AD – Twitter Chat #1

 

 

PROGRAM OVERVIEW

Although moderate-to-severe atopic dermatitis (AD) manifests on the skin’s surface, it’s far from superficial; it is a disease that originates from the deepest interior of the immune system to profoundly destabilize all psychophysical aspects of health-related quality of life. As the pathophysiology of AD has begun to unravel, it is becoming clear that to be effective, treatment needs to target the proinflammatory pathways and cytokines that are the pruritogenic core of this disease.

FACULTY

Michael S. Blaiss, MD, FACAAI
Clinical Professor of Pediatrics
Medical College of Georgia at Augusta University
Augusta, Georgia

David Stukus, MD
Associate Professor of Pediatrics
Division of Allergy and Immunology
The Ohio State University College of Medicine
Nationwide Children’s Hospital
Columbus, Ohio

 

Release date: November 4, 2020
Expiration date: November 4, 2021
Estimated time to complete activity: 60 minutes

 

TARGET AUDIENCE

This program is intended for allergists, immunologists, dermatologists, specialty advanced practice providers, and other healthcare professionals involved in the management and treatment of patients with moderate-to-severe AD.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

  • Review clinical trials outcomes and current statuses of emerging targeted therapies for moderate-to-severe AD
  • Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with Janus kinase inhibitors
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 4, 2020 through November 4, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Participate in/review the Twitter Chat
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

CREDIT DESIGNATION

Live Participation on November 4, 2020:
Integrity Continuing Education, Inc. designates this live program for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation from November 5, 2020 – November 4, 2021:
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Michael S. Blaiss, MD, FACAAI
Consulting Fees: Sanofi Regeneron

David Stukus, MD
Consulting Fees: Abbot Nutrition, Before Brands, DBV Technologies

The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.  does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash®Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Pfizer, Inc.

Continue to Pretest